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Abstract
Background: Sporadic amyotrophic lateral sclerosis (sALS) is a motor neuron disease with poorly understood
etiology. Results of gene expression profiling studies of whole blood from ALS patients have not been validated
and are difficult to relate to ALS pathogenesis because gene expression profiles depend on the relative abundance
of the different cell types present in whole blood. We conducted microarray analyses using Agilent Human Whole
Genome 4 × 44k Arrays on a more homogeneous cell population, namely purified peripheral blood lymphocytes
(PBLs), from ALS patients and healthy controls to identify molecular signatures possibly relevant to ALS
pathogenesis.
Methods: Differentially expressed genes were determined by LIMMA (Linear Models for MicroArray) and SAM
(Significance Analysis of Microarrays) analyses. The SAFE (Significance Analysis of Function and Expression)
procedure was used to identify molecular pathway perturbations. Proteasome inhibition assays were conducted on
cultured peripheral blood mononuclear cells (PBMCs) from ALS patients to confirm alteration of the Ubiquitin/
Proteasome System (UPS).
Results: For the first time, using SAFE in a global gene ontology analysis (gene set size 5-100), we show significant
perturbation of the KEGG (Kyoto Encyclopedia of Genes and Genomes) ALS pathway of motor neuron
degeneration in PBLs from ALS patients. This was the only KEGG disease pathway significantly upregulated among
25, and contributing genes, including SOD1, represented 54% of the encoded proteins or protein complexes of the
KEGG ALS pathway. Further SAFE analysis, including gene set sizes >100, showed that only neurodegenerative
diseases (4 out of 34 disease pathways) including ALS were significantly upregulated. Changes in UBR2 expression
correlated inversely with time since onset of disease and directly with ALSFRS-R, implying that UBR2 was increased
early in the course of ALS. Cultured PBMCs from ALS patients accumulated more ubiquitinated proteins than
PBMCs from healthy controls in a serum-dependent manner confirming changes in this pathway.
Conclusions: Our study indicates that PBLs from sALS patients are strong responders to systemic signals or local
signals acquired by cell trafficking, representing changes in gene expression similar to those present in brain and
spinal cord of sALS patients. PBLs may provide a useful means to study ALS pathogenesis.
Background
Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disease causing muscle weakness and
wasting resulting from the loss of motor neurons in
brain and spinal cord characterized by ubiquitinated
inclusions in brain and spinal cord of post mortem ALS
patients [1]. Several genome-wide association studies
(GWAS) have shown evidence of genetic heterogeneity
underlying disease susceptibility [2]. Single nucleotide
polymorphisms were found in the ITPR2 (inositol 1,4,5-
triphosphate receptor, type 2) [3], FGGY (FGGY carbo-
hydrate kinase domain containing) [4], DPP6 (dipepti-
dyl-peptidase 6) [5], with variable strength of association
with ALS and limited replication. None of these genes
has been proven relevant to the pathogenesis of ALS.
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(unc-13 homolog A) gene [6] and in the 9p21 chomoso-
mal locus [7]. To overcome challenges in the interpreta-
tion of results from GWAS and data from the world of
“omics” in general, ALS researchers are actively engaged
in integrative global bioinfomatics and the creation of
ALS models for development of new ALS therapies
(Euro-MOTOR project) [8]. Despite genetic heterogene-
ity underlying disease susceptibility, the clinical manifes-
tations of the ALS phenotype are relatively
homogeneous; suggesting that at the cellular and mole-
cular levels there may be a convergence of a limited
number of pathways that could lead to the ALS
phenotype.
Gene expression profiling studies using microarrays
and/or real time quantitative RT-PCR have been con-
ducted on various tissues from rodent models for ALS
such as muscle or brain tissues, lumbar spinal anterior
horn tissues, spinal cord motor neurons isolated by laser
capture microdissection (LCM), whole blood or periph-
eral blood mononuclear cells (PBMCs). Similar studies
were performed on spinal cord tissues or LCM-isolated
motor neurons obtained post mortem from ALS patients.
Roughly, ~1000 unique genes were found differentially
expressed but only ~5% differentially expressed in the
same direction in more than one study [9], indicating lit-
tle reproducibility. Poor reproducibility may be due to
the use of different gene expression profiling methods or
platforms, tissue of different origin, methods used for
biological sample preparation, time of tissue collection at
pre-symptomatic or symptomatic stage, and use of a par-
ticular batch of rodents or human cohort. Rather, one
may find greater commonalities at the pathway alteration
level with regard to apoptosis regulation, calcium regula-
tion, oxidative stress and mitochondrial function, ER-
stress and unfolded protein response (UPR), UPS and
autophagy, RNA processing, DNA metabolism, axonal
transport, integrity of the neuromuscular junction, mus-
cle atrophy, and direct/indirect interactions with astro-
cytes, microglia and T-cells. Within these biological
processes, genes of importance are those with mutations
or polymorphisms shown to confer susceptibility to or
cause ALS; or genes playing a critical role in the path-
ways that involve susceptibility genes.
A number of studies have sought blood biomarkers
that may be useful to detect early signs of ALS, assess
disease progression, monitor treatment effects, or track
down the cause(s) of the disease, in a minimally-invasive
f a s h i o ni nA L Sp a t i e n t s .U s i n gq R T - P C R ,L i net al.
(2009) have shown subtle transcriptional down-regula-
tion of mitochondrial electron-transfer chain genes in
whole blood from ALS patients [10]. Saris et al. (2009)
have identified co-expressed gene modules (clusters) in
total blood from sporadic ALS (sALS) patients [11].
These findings resulted from subtle differential expres-
sion of 2300 probe-encoded genes and were related to
biological/disease categories such as post-translational
modification, infection mechanism, inflammatory dis-
ease, neurological disorder, and skeletal and muscular
disorder. Gagliardi et al. (2010) showed increased SOD1
mRNA expression in spinal cord, brain stem and lym-
phocytes of sporadic ALS (sALS) patients [12]. Zhang et
al. (2011) identified gene expression profiles of short-
term cultured PBMCs from ALS patients, demonstrating
the activation of monocytes/macrophages via the LPS/
TLR4 neuroinflammatory pathway [13]. Lincecum et al.
(2010) demonstrated the activation in ALS pathogenesis
of a co-stimulatory pathway bridging the activation of
T-cell responses and the amplification of the innate
immune response, based on gene expression profiles
obtained from whole blood of the G93A SOD1 mouse
model and ALS patients [14]. Circulating white blood
cells might acquire certain properties from long distance
signals mediated by small metabolites or macromole-
cules circulating in peripheral blood. They might also
acquire novel properties from trafficking at sites of neu-
rodegeneration associated with rupture of the blood
brain barrier or blood-spinal cord barrier in early and
late ALS to a variable degree. Further investigation in
this area of ALS research is critically needed [15].
In the current work, we analyzed RNA extracted from
PBLs of ALS patients and control subjects, thereby
reducing some of the complexity of mixed expression
patterns generated by RNA from reticulocytes, granulo-
cytes, monocytes, thrombocytes and plasma, normally
present in whole blood. Indeed, gene expression profiles
of blood-derived samples are strongly dependent on the
predominant constituent cell type(s) [16,17]. Analyses of
mRNA expression data by LIMMA [18], SAM [19] and
SAFE [20], revealed alterations of the ubiquitin/protea-
some system (UPS). Using proteasome inhibition assays,
parallel changes of UPS activity at the protein level were
determined in subcultured PBMCs (mainly composed of
lymphocytes) from ALS patients, by Western blot
analysis.
Methods
Isolation of peripheral blood lymphocytes from ALS
patients and controls
During year 2007 until March 2008, blood samples to be
used for microarray analysis were collected at Carolinas
Neuromuscular/ALS-MDA Center with approval by the
IRB at Carolinas Medical Center. Informed consent was
obtained from all participants to this study. ALS diagno-
sis was determined according to the El Escorial Criteria
for “definite” ALS after exclusion of other conditions
[21]. Disease onset was defined as time of initial weak-
ness, dysarthria or dysphagia. Blood samples (~18 mL)
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healthy control (HC) subjects by venipuncture into tubes
adequate for either serum or lymphocyte isolation. The
healthy controls (HCs) consisted of 9 white females
(mean age 51.4 ± 11 (standard deviation) years) and 2
white males (64, 65). The sALS patients consisted of one
black male (49), one black female (69), 5 white females
(mean age 59 ± 20 years), and 4 white males (mean age
47 ± 9 years). Table 1 presents the clinical characteristics
of the enrolled patients and healthy controls subjected to
microarray analysis. PBMCs were isolated using Histopa-
que™-1077 density gradient centrifugation method.
Using this procedure, yields were generally 1-2 × 10
6
PBMCs per mL of blood. Lymphocytes were further
enriched to over 90% purity from the PBMC fraction by
subsequent PERCOLL gradient centrifugation [22]. Blood
samples were processed immediately upon reception in
the lab within 30 minutes after blood draw.
RNA extraction, amplification, and dual mode reference
design microarrays
The common reference design [23] was used for sample
assignment in the dual color mode of expression assay on
the Agilent Human Whole Genome 4 × 44k Microarrays
to analyze ~40000 transcripts. Microarray experiments
were performed, in which each of the 22 RNA samples
(HC and sALS) was co-hybridized with RNA from the
HC reference pool that was constituted with equal
amounts of each of the 11 RNA samples from healthy
controls. Total RNA stored in TRIzol (Invitrogen) at -80°
C, was extracted from the lymphocyte samples at
Cogenics, Inc. (Morrisville, NC) by standard procedures.
The quantity of each of the total RNA samples and deter-
mination of the A260/280 nm ratio was determined by spec-
trophotometry and the size distribution was assessed
using an Agilent Bioanalyzer. Fifty nanograms of total
RNA was converted into labelled cRNA with nucleotides
coupled to a fluorescent dye (either Cy3 or Cy5) using
the Quick Amp Kit (Agilent Technologies, Palo Alto,
CA) following the manufacturer’sp r o t o c o l .T h eA 260/280
nm ratio and yield of each of the cRNAs were determined
and a quality assessment was done using an Agilent Bioa-
nalyzer. Equal amounts of Cy3 and Cy5-labeled cRNA
(825 ng) from two different samples were hybridized to
Agilent Human Whole Genome 4 × 44k Microarrays.
The hybridized array was washed and scanned and data
were extracted from the scanned image using Feature
Extraction version 10.2 (Agilent Technologies). The non-
normalized and normalized microarray datasets have
been deposited in the NCBI Gene Expression Omnibus
[24] as series GSE28253.
Statistical analyses and SAFE data mining
Raw data .txt files in Agilent format were converted to .
MEV files using ExpressConverter™ v2.1 of the TM4
Microarray Suite (TIGR Genomics, Rockville, CA). Back-
ground-subtracted raw data were normalized using the
MIDAS pipeline (TM4, TIGR Genomics, Rockville, MD)
according to Sioson et al. (2006) with the following steps:
total intensity normalization, LocFit (LOWESS), standard
deviation regularization and low intensity trim [25]. Filter-
ing stringencies requiring that the integrated signal inten-
sities (ISI) for each Cy3 and Cy5 channels were more than
two standard deviation(s) of the Cy3 and Cy5 background
(ISI = 7000), generated the dataset DS7000 [7199 probes,
5540 unique genes]. DS7000 was subjected to LIMMA
[18] and SAM [19] analyses using TMeV v4.5.1 program
(TM4, TIGR Genomics, Rockville, MD) to determine dif-
ferentially expressed genes. The false discovery rate (FDR)
was 1.17% (delta = 0.90) for DS7000. SAFE analysis was
performed with Bioconductor 2.5 according to Barry,
Nobel, and Wright (2005) [20] to identify gene sets
demonstrating different expression levels between classes
of comparison. Default settings for local (t-test) and global
(Wilcoxon) statistics were used. Comparisons were based
on gene ontology databases for biological processes, mole-
cular functions, cellular components, and the protein
families (Pfam) and KEGG databases.
Total ubiquitination and proteasome inhibition assays
with PBMCs from ALS patients and healthy controls
Freshly isolated PBMCs (composed of ~80% lympho-
cytes and ~20% of monocytes per flow cytometry
Table 1 Demographic and clinical data for ALS patients
(n = 11) and healthy controls (n = 11) enrolled for
Agilent Human Whole Genome 4 × 44k Array analysis
Clinical Data at Time of Collection ALS patients Healthy controls
Mean age ± SD 53.8 ± 13 52.2 ± 11
Female 6 9
Male 5 2
Bulbar onset 2 -
Limb onset 8 -
Generalized 1 -
ALSFRS-R <24 5 -
ALSFRS-R >24 6 -
Onset of weakness ≤1y r 4 -
Onset of weakness 1-5 yrs 4 -
Onset of weakness >5 yrs 3 -
Mean age of onset ± SD 47.2 ± 18 -
Death <3 yrs post-onset 3 -
Death >5 yrs post-onset 2 -
Mean age of death (n = 5) ± SD 62.2 ± 12 -
Three subjects with an ALSFRS-R >24 died within three years (1.5, 2, and 2.5
years) following ALS onset, and two others with an ALSFRS-R <24 died
beyond 5 years (7.5 and 9.5 years). Some ALS patients were treated with
riluzole (5 out of 11) and taking dietary supplements (7 out of 11) compared
to healthy controls which are not matched in this regard. SD is standard
deviation.
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subcultured overnight (O.N.) for 18 hr at 37°C in RPMI
(Invitrogen) supplemented with 10% FCS (Invitrogen)
and supplemented or not with added-back matched
autologous serum that had been prepared in parallel.
These PBMCs were treated, or not treated, for 1.5 hrs at
37°C with the reversible proteasome inhibitor MG132
(Sigma). For each patient or healthy control, serum was
prepared separately from PBMCs from the same blood
draw. Matched serum was supplemented at a concentra-
tion of 20% to the O.N. cultures. A total of 750000 cells
were seeded per well of a 48-well plate. Cells were trea-
ted with 10 μM proteasome inhibitor MG132 or DMSO
vehicle at 0.09% for 1.5 hrs. Cells were collected and
snap frozen until Western blot analysis. Cells were lysed
into RIPA buffer (150 mM NaCl, 1.0% IGEPAL
® CA-
630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris,
pH 8.0) including protease inhibitor cocktails [complete
Mini EDTA-free protease inhibitor cocktail tablets
(Roche) and Protease Inhibitor cocktail P8340 (Sigma)].
Total protein was quantified using BioRad Dc protein
assay. An aliquot (20 μg total protein) was supplemen-
ted with 2x Laemmli’s sample buffer and boiled for 5
minutes prior to separation by sodium dodecyl sulfate
(SDS)-12.5% polyacrylamide gel electrophoresis for 130
min at 100V. Proteins were transferred to polyvinylidene
difluoride membranes (Millipore) and quenched with
blocking buffer containing 10% non-fat milk in PBS-0.1
Tween 20 for 1 hr at room temperature. The mem-
branes were incubated overnight at 4°C with primary
monoclonal anti-ubiquitin sc-8017 antibody (1/1000
dilution; Santa Cruz) diluted in the blocking buffer.
Membranes were subsequently incubated with goat anti-
mouse human absorbed HRP-secondary sc-2055 anti-
body (1/10000 dilution; Santa Cruz) for 30 minutes and
assayed using the Super Signal Pico chemiluminescence
detection system (Thermo Fisher Scientific). Subsequent
reprobing with anti-beta-actin antibody sc-81178 (Santa
Cruz) was performed by stripping membranes of bound
antibodies in stripping buffer (62.5 mM Tris HCL, 2%
SDS, and 100 mM 2-mercaptoethanol [pH 6.7]) at 56°C
for 20 minutes. ECL films and a LAS3000 imaging sys-
tem (Fuji) were used for detection of the chemilumines-
cence. Silver staining was used to confirm loading
homogeneity in the PAGEs post-electrotransfer using
SilverSNAP stain (Thermo Fisher Scientific), in addition
to reprobing of the membranes for beta-actin.
Semi-quantitative analysis of the Western blot data
Raw images were processed in ImageJ program (Dr.
Wayne Rasband, wayne@codon.nih.gov, National Insti-
tute of Mental Health, Bethesda, Maryland, USA). The
accumulated HMW ubiquitinated protein forms were
delineated by a rectangular area, for which the
background subtracted integrated density could be mea-
sured. The integrated density could then be measured
for same area below the accumulated forms at a level of
the blotting membrane demonstrating consistency of
staining throughout the lanes, thereby providing a con-
trast reference area per lane. Calculation of a signal-to-
noise (S/N) ratio for the accumulated forms was then
determined independently from the detection of beta-
actin that was achieved by stripping and reprobing the
Western blot membranes.
Results
We studied gene expression profiles of lymphocytes iso-
lated from 11 patients diagnosed with definite sporadic
ALS (sALS) and 11 healthy control subjects. Clinical
characteristics for this cohort are described in Table 1.
Figure 1 summarizes results from microarray data nor-
malization and LIMMA, SAM and SAFE analyses.
LIMMA and SAM analyses
Differentially expressed genes between ALS patients and
healthy controls were determined using LIMMA
(pLIMMA <0 . 0 0 1 ,q LIMMA ≤ 10%) and SAM (qSAM ≤ 1%)
in TM4/TMeV v4.5.1 program [25] for the dataset
DS7000 (Figure 1). A significant overlap was found by
comparing LIMMA and SAM results (Figure 1, Addi-
tional File 1). Table 2 presents the 24 most differentially
expressed genes (qSAM =0 % ,p LIMMA < 0.0005, qLIMMA
≤ 10%). Five genes (C12orf35, DYNLT1, IRS2, SKIV2L2,
and TARDBP) were significant at high stringency (qSAM
=0 % ,p LIMMA < 0.001, qLIMMA <5 % ) .C12orf35,
DYNLT1, SKIV2L2,a n dTARDBP were upregulated 1.5-
1.8 fold change (FC), while IRS2 was downregulated by
two fold. DYNLT1 (dynein, light chain, Tctex-type 1)
encodes a component of the dynein-dynactin complex
composed of dynactin (DCTN1), those mutations have
been involved in ALS [26], while TARDBP encodes TAR
DNA binding protein 43 (TDP-43), those mutations
may cause ALS [27]. TIA-1, a marker of stress granules
that colocalizes with TDP-43 inclusions in frontotem-
poral lobar degeneration (FTLD-U) and ALS [28], is
also upregulated (FC = 1.4, qSAM =0 % ,p LIMMA <0 . 0 0 5 ,
qLIMMA~10%; Additional File 1. SKIV2L2 encodes a
DEAD-box RNA helicase which is part of the exosome
and spliceosome complexes [29,30] and it is known, for
example, that some DEAD-box RNA helicases interact
with FUS/TLS to control pre-mRNA splicing [31].
Defects or deregulation in RNA processing are a hall-
mark in the pathogenesis of motor neuron diseases,
since motor neurons may be uniquely sensitive to per-
turbations in RNA processing pathways [32]. We also
note that IL7R (interleukin-7 receptor subunit alpha),
polymorphisms of which have been associated with risk
in multiple sclerosis [33], is upregulated (FC = 1.7, qSAM
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Page 4 of 19Figure 1 Normalization, filtering, SAFE, LIMMA and SAM analyses of lymphocyte-derived microarray data from ALS patients and
healthy controls. Microarray analyses were performed on purified PBLs isolated from patients affected by sporadic amyotrophic lateral sclerosis
(sALS) (n = 11) and healthy control subjects (HCs) (n = 11). The dual color mode in the common reference design was used to interrogate the
expression of ~40000 transcripts (~30000 unique genes) using Agilent Human Whole Genome 4 × 44k Microarrays. Raw expression data were
normalized and filtered using the MIDAS pipeline in the TM4 microarray suite (TIGR Genomics, Rockville, MD) to generate the dataset DS7000.
SAFE was used for testing enrichment of functional gene ontology (GO) categories related to biological processes, molecular functions, cellular
components, protein families (Pfam) and the KEGG databases. DS7000 was subjected to LIMMA and SAM analyses using TM4/TMeV v4.5.1 to
determine differentially expressed (DE) genes. The online tool Data Overlapping and Area-Proportional Venn Diagram (http://bioinforx.com/free/
bxarrays/overlap.php) was used to generate the Venn diagram.
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tified upregulation (FC = 1.4, qSAM~0.5%, pLIMMA <
0.005, qLIMMA~10%) of RTN4IP1 (reticulon 4 interacting
protein alias NOGO-interacting mitochondrial protein),
a mitochondrial protein that interacts with reticulon 4, a
potent inhibitor of regeneration following spinal cord
injury [34]. We also identified upregulation of SOD1
(FC = 1.3, q~1%, pLIMMA<0.05, qLIMMA~10%), confirm-
ing the work by Gagliardi et al. (2010) [12].
SAFE identification of molecular signatures in
lymphocytes from ALS patients
SAFE [20] is a resampling-based procedure that is simi-
lar to GSEA (Gene Set Enrichment Analysis) [35], but
with more flexible choices of test statistics. SAFE was
used to obtain information on unifying biological
themes from databases specific for (i) gene ontology
(GO) pathways/categories (biological process, cellular
component and molecular function), (ii) pathways/cate-
gories defined by the KEGG (Kyoto Encyclopedia of
Genes and Genomes) and (iii) Pfam (protein families).
Such resampling procedures have been shown to pro-
vide more accurate control of false positives than sim-
pler enrichment-test methods using only lists of p-
values [36].
Following determination of local (t-test) and global
(Wilcoxon test) statistics using SAFE default settings,
the significance for each gene set category was deter-
mined by bootstrap re-sampling and multiple test cor-
rection (for the multiple categories examined) by an
FDR procedure with qSAFE < 25% considered significant
(similarly to GSEA). This relatively liberal threshold was
intended to avoid false negatives, although many of the
findings presented here achieve more striking signifi-
cance. For SAFE gene ontology category analysis, gene
sets of 5-100 genes were examined, similar to restric-
tions used by others (e.g.,B a r r yet al., 2005) [20]. This
approach ensures that gene sets were not so small as to
call into question a “pathway” interpretation, and not so
large as to defy biological interpretation. In addition, the
approach helps to manage the multiple testing penalties
across numerous categories. To simplify overall
Table 2 Differentially expressed genes in peripheral blood lymphocytes from ALS patients by SAM (q = 0) ranked by
independent LIMMA (p < 0.0005)
aProbe
bSymbol
gGene Description
δp
value
εq
value
cFC
A23P8185 DYNLT1 dynein, light chain, Tctex-type 1 0.000004 0.028 1.5
A24P154037 IRS2 insulin receptor substrate 2 0.000015 0.048 0.5
A32P234935 TARDBP TAR DNA binding protein 0.000024 0.048 1.6
A23P98930 C12orf35 chromosome 12 open reading frame 35 0.000031 0.048 1.6
A23P110661 SKIV2L2 superkiller viralicidic activity 2-like 2 0.000033 0.048 1.8
A23P104624 ENDOD1 endonuclease domain containing 1 0.000069 0.083 1.5
A23P317800 ANAPC4 anaphase promoting complex subunit 4 0.000106 0.100 1.4
A23P21673 KIAA1797 KIAA1797 0.000150 0.100 1.5
A23P145437 PHIP pleckstrin homology domain interacting protein 0.000185 0.100 1.4
A23P15714 NSF N-ethylmaleimide-sensitive factor 0.000210 0.100 1.6
A23P82588 C7orf55 chromosome 7 open reading frame 55 0.000234 0.100 1.6
A23P120153 RNF149 ring finger protein 149 0.000290 0.100 1.7
A23P70998 tcag7.903 full-length cDNA clone CS0DF028YG12 0.000308 0.100 1.5
A23P145874 SAMD9L sterile alpha motif domain containing 9-like 0.000310 0.100 2.1
A24P172481 TRIM22 tripartite motif-containing 22 0.000319 0.100 1.5
A23P42664 SHFM1 split hand/foot malformation (ectrodactyly) type 1 0.000328 0.100 1.6
A23P156355 TMEM161B transmembrane protein 161B 0.000340 0.100 1.5
A23P129925 SLFN11 schlafen family member 11 0.000364 0.100 1.5
A24P209455 GIMAP4 GTPase, IMAP family member 4 0.000383 0.100 1.8
A23P84775 PLRG1 pleiotropic regulator 1 0.000386 0.100 1.5
A23P213255 SMARCAD1 SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a,
containing 1 DEAD/H box 1
0.000445 0.100 1.6
A23P19565 ASCC3 activating signal cointegrator 1 complex subunit 3 0.000457 0.100 1.4
A23P61854 KIAA0372 tetratricopeptide repeat protein 37 0.000461 0.100 1.4
A23P91891 COPB2 coatomer protein complex, subunit beta 2 0.000471 0.100 1.9
The list presents the 24 most discriminatory genes distinguishing the definite sALS patients (n = 11) from the healthy control subjects (n = 11).
aAgilent Array 4
× 44K probe ID,
bgene symbol,
gdescription,
δLIMMA significance p value,
εLIMMA FDR (q value), and
cfold change (FC) in expression are indicated. Using the
TM4-MIDAS/TMeV pipeline, all genes had a local FDR of q = 0 according to SAM performed on DS7000 [7199 probes, 5540 unique genes]. Five genes had a
LIMMA q value ≤0.05: DYNLT1, IRS2, TARDBP, C12orf35, and SKIV2L2.
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to highlight pathway activations caused by the disease
rather than pathway inhibitions.
Significant upregulated categories representing gene
sets associated with “biological processes”, “cellular com-
ponents”,a n d“KEGG pathways” are shown in Tables 3,
4 and 5. We used same gene set size restriction (5-100
genes) for SAFE analysis of KEGG gene ontology groups
including the KEGG Human Disease pathways, of which
25 were annotated in Bioconductor 2.5 for the Agilent
platform. We identified that the KEGG ALS pathway
was significant (qSAFE = 18%). The KEGG ALS pathway
Table 3 SAFE gene ontology pathways related to Biological Processes affected in peripheral blood lymphocytes from
ALS patients
aPathway
bSizes
δq-value
εGO Term
DNA Metabolism
GO:0006310 54/71 0 DNA recombination
GO:0006302 27/50 0.003 double-strand break repair
GO:0000718 12/21 0.0414 nucleotide-excision repair DNA damage removal
ER and Golgi
GO:0006895 6/7 0.0071 Golgi to endosome transport
GO:0006888 26/43 0.1127 ER to Golgi vesicle-mediated transport
GO:0006904 10/19 0.0071 vesicle docking during exocytosis
GO:0006892 11/41 0.0471 post-Golgi vesicle-mediated transport
GO:0007041 7/6 0.1885 lysosomal transport
Mitochondrial Function
GO:0022904 53/98 0.0558 mitochondrial ATP synthesis coupled electron transport
respiratory electron transport chain
GO:0006120 44/43 0.0523 mitochondrial electron transport NADH to ubiquinone
GO:0006626 17/25 0.0972 protein targeting to mitochondrion
GO:0006119 81/8 0.1 oxidative phosphorylation
Neurological Function
GO:0010001 8/13 0.1 glial cell differentiation
GO:0042552 8/30 0.1138 myelination
Oxidation
GO:0019395 19/6 0.2252 fatty acid oxidation
RNA Metabolism
GO:0000387 25/26 0.003 spliceosomal snRNP biogenesis
GO:0033119 10/3 0.0071 negative regulation of RNA splicing
GO:0051028 81/62 0.0644 mRNA transport
PTM
GO:0070206 7/7 0 protein trimerization
GO:0018279 8/47 0.0071 protein amino acid N-linked glycosylation via asparagine
GO:0051262 10/12 0.0644 protein tetramerization
GO:0006465 7/9 0.0835 signal peptide processing
GO:0045116 8/7 0.0644 protein neddylation
GO:0016925 15/11 0.0627 protein sumoylation
UPS
GO:0051443 62/6 0.0644 positive regulation of ubiquitin-protein ligase activity
GO:0051444 59/4 0.0644 negative regulation of ubiquitin-protein ligase activity
GO:0043161 79/43 0.0644 proteasomal ubiquitin-dependent protein catabolic process
Viral Infection
GO:0019047 11/8 0.044 provirus integration
GO:0019059 18/12 0.0852 initiation of viral infection
GO:0019058 41/92 0.0644 viral infectious cycle
aGene ontology (GO) pathway identities for biological processes and
bnumber of probes represented on the 4 × 44K human genome array per GO group of
directly associated proteins is shown (note: one gene may be represented by different or redundant probes on the array).
gFDR (q-value) at significance level p <
0.25 (25%) was determined by bootstrapping following SAFE analysis.
δThe table shows partial listing of representative significant
εGO categories associated with
biological processes (30 among 99). UPS is ubiquitin/proteasome system, PTM is post-translational modification, and ER is endoplasmic reticulum.
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Page 7 of 19Table 4 SAFE gene ontology pathways related to Cellular Components affected in peripheral blood lymphocytes from
ALS patients
aPathway
bSizes
δq-value
εGO Term
Cytoskeleton
GO:0005868 6/10 0.001 cytoplasmic dynein complex
GO:0005885 8/7 0.0322 Arp2/3 protein complex
ER and Golgi
GO:0030130 9/9 0.0001 clathrin coat of trans-Golgi network vesicle
GO:0008250 8/10 0.0001 oligosaccharyltransferase complex
GO:0030660 23/6 0.0001 Golgi-associated vesicle membrane
GO:0030134 7/3 0.0057 ER to Golgi transport vesicle
GO:0005791 12/20 0.0613 rough endoplasmic reticulum
GO:0030131 18/19 0.024 clathrin adaptor complex
GO:0030119 18/5 0.024 AP-type membrane coat adaptor complex
GO:0001669 8/34 0.2372 acrosomal vesicle
GO:0030127 6/8 0.0122 COPII vesicle coat
GO:0030126 8/12 0.003 COPI vesicle coat
Mitochondria
GO:0005758 22/30 0.0004 mitochondrial intermembrane space
GO:0005763 20/18 0.0002 mitochondrial small ribosomal subunit
GO:0000276 7/8 0.0006 mitochondrial proton-transporting ATP synthase complex coupling factor F(o)
GO:0005747 44/44 0.0126 mitochondrial respiratory chain complex I
GO:0005742 6/6 0.024 mitochondrial outer membrane translocase complex
Motor Neuron
GO:0031594 8/25 0.028 neuromuscular junction
GO:0030424 21/133 0.1525 axon
Nucleus
GO:0005680 12/24 0.0167 anaphase-promoting complex
GO:0000777 18/61 0.1854 condensed chromosome kinetochore
GO:0000779 20/4 0.1989 condensed chromosome centromeric region
GO:0000783 9/9 0.1197 nuclear telomere cap complex
GO:0005643 51/67 0.2084 nuclear pore
GO:0005637 10/28 0.1318 nuclear inner membrane
Transcriptional Complexes
GO:0016591 43/6 0.001 DNA-directed RNA polymerase II holoenzyme
GO:0000178 11/9 0.0025 exosome (RNase complex)
GO:0016580 10/8 0.0712 sin3 complex
GO:0005669 11/20 0.1817 transcription factor TFIID complex
UPS
GO:0005832 5/7 0.0001 chaperonin-containing T-complex
GO:0000151 57/57 0.0003 ubiquitin ligase complex
GO:0000152 14/2 0.024 nuclear ubiquitin ligase complex
GO:0031461 10/8 0.0012 cullin-RING ubiquitin ligase complex
GO:0005839 20/14 0.0167 proteasome core complex
GO:0016272 8/10 0.0402 prefoldin complex
GO:0008180 8/10 0.003 signalosome
aGene ontology (GO) pathway identities for cellular components and
bnumber of probes on the 4 × 44K human genome array per GO group of directly
associated proteins is shown (note: one gene may be represented by different or redundant probes on the array).
gFDR (q-value) at significance level q < 0.25
(25%) was determined by bootstrapping following SAFE analysis.
δThe table shows partial listing of representative significant
εGO categories associated with
cellular components (36 among 83). UPS stands for the ubiquitin/proteasome system and ER for endoplasmic reticulum.
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Page 8 of 19was the only significantly upregulated disease pathway
among the 25 disease pathways (Additional File 2). In
addition, we considered all 34 KEGG Human Disease
pathways annotated in Bioconductor 2.5 for the Agilent
platform among 55 total represented in the KEGG data-
base (http://www.genome.jp/kegg-bin/get_htext?
htext=br08901&query=%22Human%20Diseases%
22&option=-s) [37] by including gene set sizes >100 in a
secondary analysis.
We found that only neurodegenerative disease path-
ways (4 in total) were significantly upregulated (Addi-
tional File 2). In this latter analysis, ALS was less
significant than the other three neurodegenerative dis-
eases (Huntington’s disease, Parkinson’sd i s e a s e ,A l z h e i -
mer’s disease), suggesting that neurodegeneration affects
lymphocytes to a greater extent than ALS-specific biolo-
gical processes. Nevertheless, such interpretation has to
be taken with caution. Indeed, some genes represented
on the pathway maps of these other three neurodegen-
erative diseases are related to the UPS, cytoskeleton or
dynein-dynactin complex, and therefore should be
represented on the KEGG ALS pathway. However, ALS,
Alzheimer’s, Huntington’s and Parkinson’s are all neuro-
degenerative diseases related to aging and/or associated
with mitochondrial dysfunction. For this reason, results
are in alignment with the results of Saris et al. (2009)
[11]. Prion disease, generally thought to be less related
to the other neurodegenerative disorders, was found not
significant (Additional File 2).
A total of 54 unique gene IDs (including the pseudo-
gene caspase 12) constitute the KEGG ALS pathway
(hsa05014) [37] and correspond to 36 protein entities
defining unique proteins or protein complexes (Figure
2). A total of 35 protein entities corresponding to 53
genes represented on the KEGG ALS pathway map
(pseudogene CASP12 excluded) include membrane
receptors, cytosolic or secreted proteins, kinases, phos-
phatases, proteases, and protein channels, which are
likely to play a direct/indirect role in ALS pathogenesis
to a variable degree at different stages that lead to
motor neuron degeneration. Some protein entities may
correspond to different isoforms represented by unique
gene IDs. For example, calcineurin (CaN entity) may be
composed by three catalytic isoforms (a,b,g)e n c o d e db y
three different chromosomes and many types of gluta-
mate receptors may represent the GluR entity (Figure 2).
T h e r ew e r e2 3u n i q u eg e n e s( 4 3 % ,8 1p r o b e s ) ,t h e
aggregate expression pattern of which contributes to the
perturbation of the KEGG ALS pathway (Table 6). The
number of protein entities defined by these genes and
represented on the KEGG ALS pathway map was 19 out
of 35 (54%) (Table 6, Figure 2). The dynamics of up-
and down-regulations, assuming they are functionally
effective, may be interpreted as responses to signals ori-
ginating from serum or cell-cell interactions. For exam-
ple upregulation of ASK1 (alias MAP3K5)m a yb e
associated with an ER-stressr e s p o n s et h a tc o r r e l a t e s
with ALS progression (Figure 2). Also, assuming that
Table 5 SAFE analysis of the KEGG pathway database
aPathway
(UP)
bSize
δq-
value
εGO Term
Disease
KEGG:05014 92/54 0.1831 Amyotrophic lateral sclerosis
DNA Metabolism
KEGG:03030 35/36 0.2048 DNA replication
KEGG:03410 46/34 0.0003 Base excision repair
KEGG:03420 42/44 0.0758 Nucleotide excision repair
KEGG:03430 36/23 0.1367 Mismatch repair
KEGG:03440 13/28 0.0003 Homologous recombination
RNA Metabolism
KEGG:03018 55/54 0.0007 RNA degradation
KEGG:03020 16/29 0.0296 RNA polymerase
KEGG:00970 18/63 0.005 Aminoacyl-tRNA biosynthesis
Mitochondrial Function
KEGG:00062 5/8 0.0381 Fatty acid elongation in mitochondria
KEGG:00071 17/44 0.1726 Fatty acid metabolism
Amino acid Metabolism
KEGG:00270 22/36 0.0261 Cysteine and methionine metabolism
KEGG:00280 24/44 0.025 Valine leucine and isoleucine
degradation
KEGG:00290 7/11 0.0072 Valine leucine and isoleucine
biosynthesis
KEGG:00310 24/44 0.0385 Lysine degradation
KEGG:00450 13/26 0.2048 Selenoamino acid metabolism
Carbohydrate Metabolism
KEGG:00632 8/33 0.0003 Benzoate degradation via CoA
ligation
KEGG:00640 18/32 0.0381 Propanoate metabolism
KEGG:00650 13/30 0.0003 Butanoate metabolism
KEGG:00670 8/18 0.0177 One carbon pool by folate
KEGG:00903 7/32 0.0425 Limonene and pinene degradation
KEGG:00510 31/49 0.2155 N-Glycan biosynthesis
Cell-Cell
Communication
KEGG:04330 35/47 0.2288 Notch signaling pathway
Chaperone-dependent protein transport
KEGG:03060 13/23 0.0573 Protein export
Neuromuscular
KEGG:04260 46/77 0.1493 Cardiac muscle contraction
UPS
KEGG:03050 42/45 0.032 Proteasome
KEGG:04120 93/
138
0.032 Ubiquitin mediated proteolysis
aKEGG pathway identities and
bnumber of probes of the array mapping to
the pathway per number of unique genes representing the pathway is shown.
FDR (q-value) at significance level p < 0.25 (25%) was determined by
bootstrapping following SAFE analysis.
εThe table shows listing of the 27
significant KEGG pathway categories. UPS stands for the ubiquitin/proteasome
system.
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Page 9 of 19transcriptional regulation produces more or less active
protein with appropriate subcellular localization and in
a timely manner, about half of the genes would have a
negative effect on motor neuron survival while the rest
would have a positive effect according to current ALS
literature. This said contribution of aggregate expression
to a pathway does not necessarily signify differential
expression of each participant gene in terms of differ-
ences between the mean expression levels in lympho-
cytes from ALS vs. healthy controls. One limitation is
that individual protein entities of the UPS, the dynein-
dynactin complex, and TARDBP/TDP43 pathway and
other elements of ALS pathogenesis are not represented
on the KEGG ALS pathway, so that other potential
aggregate effects relevant of ALS pathogenesis cannot
be determined using the current gene set. However,
pathway perturbations were determined by SAFE for
genes belonging to the UPS both in terms of “biological
process” and “cellular components” affected (Tables 3
and 4). Gene ontology categories corresponding to gene
sets related to the UPS (AmiGO database) [38] included
the following: positive or negative regulation of ubiqui-
tin-protein ligase, proteasomal ubiquitin-dependent pro-
teins [GO:0051443, 6 proteins; GO:0051444, 4 proteins;
GO:0043161, 43 proteins] (Table 3); chaperonin-con-
taining T-complex, ubiquitin ligase complex, nuclear
Figure 2 Genes from lymphocytes of ALS patients contributing to the perturbation of the KEGG ALS pathway per SAFE analysis. The
KEGG (Kyoto Encyclopedia of Genes and Genomes) ALS pathway map relates to motor neuron degeneration in the context of a
microenvironment represented by glial cells and can be found online at http://www.genome.jp/kegg/pathway/hsa/hsa05014.html. There are 54
unique gene entries (including CASP12 pseudogene) defined by ENTREZ identities. There are 36 protein entities represented on the map that are
not all designated by official HUGO gene symbols. Red dashed areas represent subpathway modules affected by differentially expressed genes.
Up or down-regulations determined following SAFE for DS7000 are shown by (↑)o r( ↓), unchanged is shown by (=) (fold changes in expression
and HUGO gene symbols are reported in Table 6). HUGO aliases for protein entities represented on the map are as follows: ALS2 [ALS2], Apaf1
[APAF1], ASK1 [MAP3K5], Bad [BAD], Bax [BAX], Bcl2 [BCL2], Bcl-XL [BCL2L1], Bid [BID], CaN [CHP, CHP2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2],
CASP1 [CASP1], CASP3 [CASP3], CASP9 [CASP9], CASP12 [CASP12], CAT [CAT], CCS [CCS], CytC [CYCS], Daxx [DAXX], Derlin-1 [DERL1], EAAT2
[SLC1A2], GPX1 [GPX1], GluR [GRIA1, GRIA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D], MKK3 [MAP2K3], MKK6 [MAP2K6], p38 [MAPK11, MAPK12,
MAPK13, MAPK14], NEFH [NEFH], NEFL [NEFL], NEFM [NEFM], NOS1 [NOS1], p53 [TP53], PRPH [PRPH, PRPH2], Rab5 [RAB5A], Rac1 [RAC1], SOD1
[SOD1], TNF-a [TNF], TNFR [TNFRSF1A, TNFRSF1B], and Tom [TOMM40, TOMM40L].
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Page 10 of 19Table 6 Genes differentially expressed in lymphocytes from ALS patients compared to healthy controls and
contributing to the KEGG ALS pathway as determined by SAFE
aEntrez Gene ID
bSymbol
gDescription
δSAFE
εPS/PT
lFC
Effect in ALS
τLR
57679 ALS2 amyotrophic lateral sclerosis 2 (juvenile) - n.d. < ↓ - [11586298] n.d.
317 APAF1 apoptotic peptidase activating factor 1 - n.d. < ↑ - [16046141] n.d.
572 BAD BCL2-associated agonist of cell death + 1/1 1.38 ↓↑- [19043451] +
581 BAX BCL2-associated X protein + 10/11 1.11 ↓↑- [17171827] +
596 BCL2 apoptosis regulator B-cell CLL/lymphoma 2 + 10/11 1.07 ↑↑+ [20460269] +
598 BCL2L1 inhibitor of cell death BCL2-like 1 - n.d. < ↑ + [12097494] n.d.
637 BID BH3 interacting domain death agonist + 1/2 < ↑ - [12213439] n.d.
834 CASP1 caspase 1, apoptosis-related cysteine peptidase + 1/1 1.54 ↑↑- [10764647] -
836 CASP3 caspase 3, apoptosis-related cysteine peptidase + 10/10 1.20 ↑↑- [10764647] -
842 CASP9 caspase 9, apoptosis-related cysteine peptidase - 2/2 1.07 ↑↑- [14657037] -
847 CAT catalase (heme containing) + 1/1 1.46 ↑↑+ [8731383] +
9973 CCS copper chaperone for superoxide dismutase - 1/1 1.08 ↓↓- [17389365] -
11261 CHP calcineurin B homolog + 1/1 1.16 ↑↑+ [11350981] +
63928 CHP2 calcineurin B homologous protein 2 - n.d. < ↑ + [12226101] n.d.
54205 CYCS cytochrome c, somatic + 2/3 1.10 ↑↓- [17454840] +
1616 DAXX death-domain associated protein - n.d. < ↑ - [12354397] n.d.
79139 DERL1 degradation in endoplasmic reticulum protein 1 + 1/1 < ↑ - [18519638] n.d.
2876 GPX1 glutathione peroxidase 1 + 1/1 1.22 ↓↓- [9335008] -
2890 GRIA1 glutamate receptor, ionotropic, AMPA 1 - n.d. < ↓ - [8981413] n.d.
2891 GRIA2 glutamate receptor, ionotropic, AMPA 2 - n.d. < ↓ - [8981413] n.d.
2902 GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 + 2/2 1.44 ↓↓- [1320444] -
2903 GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A - n.d. < ↓ - [8842405] n.d.
2904 GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B - n.d. < ↓ + [16490316] n.d.
2905 GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C - n.d. < ↓ + [11717388] n.d.
2906 GRIN2D glutamate receptor, ionotropic, N-methyl D-aspartate 2D + 1/1 1.58 ↓↑+ [15152019] -
5606 MAP2K3 mitogen-activated protein kinase kinase 3 + 1/1 1.34 ↓↑- [17686961] +
5608 MAP2K6 mitogen-activated protein kinase kinase 6 - 1/1 1.32 ↑↑- [16219474] -
4217 MAP3K5 mitogen-activated protein kinase kinase kinase 5 + 1/1 1.10 ↑↑- [15910777] -
5600 MAPK11 mitogen-activated protein kinase 11 - n.d. < ↑ - [9218798] n.d.
6300 MAPK12 mitogen-activated protein kinase 12 - n.d. < ↑ - [9169156] n.d.
5603 MAPK13 mitogen-activated protein kinase 13 - n.d. < ↑ - [9218798] n.d.
1432 MAPK14 mitogen-activated protein kinase 14 + 10/10 1.26 ↑↑- [15910777] -
4744 NEFH neurofilament, heavy polypeptide - n.d. < ↓ - [7849698] n.d.
4747 NEFL neurofilament, light polypeptide - n.d. < ↓ - [15207859] n.d.
4741 NEFM neurofilament, medium polypeptide - n.d. < ↓ - [11732278] n.d.
4842 NOS1 nitric oxide synthase 1 (neuronal) - n.d. < ↑ - [15033415] n.d.
5530 PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme + 3/3 1.06 ↑↓- [11701756] +
5532 PPP3CB protein phosphatase 3, catalytic subunit, beta isozyme + 1/1 1.28 ↑↓- [15312178] +
5533 PPP3CC protein phosphatase 3, catalytic subunit, gamma isozyme + 1/1 < ↓ - [15312178] n.d.
5534 PPP3R1 protein phosphatase 3, regulatory subunit B, alpha - n.d. < ↓ - [11754729] n.d.
5535 PPP3R2 protein phosphatase 3, regulatory subunit B, beta - n.d. < ↓ - [11754729] n.d.
5630 PRPH peripherin - n.d. < ↓ - [20363051] n.d.
5961 PRPH2 peripherin 2 - n.d. < ↓ - [8125718] n.d.
5868 RAB5A ras-related protein Rab-5A + 1/1 1.11 ↓↓+ [11316809] +
5879 RAC1 ras-related C3 botulinum toxin substrate 1 + 12/12 1.08 ↓↓- [18219391] -
6506 SLC1A2 sodium-dependent glutamate/aspartate transporter 2 - n.d. < ↑ + [14530974] n.d.
6647 SOD1 superoxide dismutase 1, soluble + 11/11 1.24 ↑↓- [20644736] +
7124 TNF tumor necrosis factor alpha + 1/1 1.15 ↑↑+ [18823372] +
7132 TNFRSF1A tumor necrosis factor receptor superfamily, member 1A - n.d. < ↑ - [11917000] n.d.
7133 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B - n.d. < ↓ + [11917000] n.d.
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Page 11 of 19ubiquitin ligase complex, cullin-RING ubiquitin ligase
complex, proteasome core complex, prefoldin complex,
and signalosome [GO:0005832, 7 proteins; GO:0000151,
57 proteins; GO:0000152, 2 proteins; GO:0031461, 8
proteins; GO:0005839, 14 proteins, GO:0016272, 10
proteins; GO:0008180, 10 proteins] (Table 4). Consider-
ing gene listing overlaps, UPS GO categories for biologi-
cal processes and cellular components found significant
by SAFE, represent altogether 234 unique proteins
defined by official HUGO (Human Genome Organiza-
tion) gene nomenclature. Among 220 unique genes that
were differentially expressed, as determined by SAM
and LIMMA, (Figure 1, Additional File 1), nine are
related to the UPS, including four E3 ubiquitin ligases
(RNF149, TRIM22, UBR1,a n dUBR2)( T a b l e7 ) .A l s o ,
ANAPC4, SHFM1, SUGT1, UBR1 and UBR2 were
represented by the UPS GO groups found significant by
SAFE.
Table 6 Genes differentially expressed in lymphocytes from ALS patients compared to healthy controls and contribut-
ing to the KEGG ALS pathway as determined by SAFE (Continued)
10452 TOMM40 mitochondrial import receptor subunit TOM40 homolog - n.d. < ↓ - [20797528] n.d.
84134 TOMM40L mitochondrial import receptor subunit TOM40B - 1/1 1.23 ↓↓- [20797528] -
7157 TP53 tumor protein p53 - n.d. < ↑ - [8609941] n.d.
Genes (53 in total, pseudogene CASP12 excluded) belonging to the KEGG ALS pathway (hsa05014) that describe pathogenic effects in motor neurons are defined
by their official HUGO symbol.
aEntrez Gene accession number and
bHUGO symbol and
gdescription are provided.
δGenes that contribute to the KEGG ALS
pathway through SAFE analysis are marked with a (+) sign and if not with a (-) sign. Number of probes significant (PS) per total number of probe signal intensity
values per gene on the Agilent 4 × 44K array (PT) is shown.
lFC is average fold change ALS (n = 11) compared to healthy controls (n = 11) considering one or
more probe signal intensity values per gene, with upregulated genes indicated by (↑) and downregulated genes by (↓). Less than 1.05 fold changes are indicated
by (<).
PMID referenced positive (+) or negative (-) effect on motor neuron survival if wild type protein activity or function is increased (↑) or normal function or
activity is altered (↓). Genes that were not determined (n.d.) to contribute to the KEGG ALS pathway or with an FC < 1.05, are also referenced for known effects.
τLymphocyte response (LR) represented by the genes contributing to the KEGG ALS pathway is shown.
Table 7 Differentially expressed genes related to the UPS, as determined by SAM and LIMMA
aProbe
bSymbol
gAccession
δFC
εFunctional Description
A_23_P317800 ANAPC4 NM_013367 1.40 anaphase promoting complex subunit 4: Component of the anaphase promoting complex/cyclosome
(APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the
G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent
degradation of target proteins: it mainly mediates the formation of ‘Lys-11’-linked polyubiquitin chains
and, to a lower extent, the formation of ‘Lys-48’- and ‘Lys-63’-linked polyubiquitin chains
A_23_P106741 PSMD7 NM_002811 1.41 proteasome (prosome, macropain) 26S subunit, non-ATPase, 7: Acts as a regulatory subunit of the 26S
proteasome which is involved in the ATP-dependent degradation of ubiquitinated proteins
A_23_P120153 RNF149 NM_173647 1.67 E3 ubiquitin-protein ligase RNF149: Unknown
A_23_P42664 SHFM1 NM_006304 1.63 split hand/foot malformation (ectrodactyly) type 1: Subunit of the 26S proteasome which plays a role in
ubiquitin-dependent proteolysis
A_24_P172481 TRIM22 NM_006074 1.55 E3 ubiquitin-protein ligase TRIM22: Interferon-induced antiviral protein involved in cell innate immunity.
The antiviral activity could in part be mediated by TRIM22-dependent ubiquitination of viral proteins.
Plays a role in restricting the replication of HIV-1, encephalomyocarditis virus (EMCV) and hepatitis B
virus (HBV). Acts as a transcriptional repressor of HBV corepromoter. May have E3 ubiquitin-protein
ligase activity.
A_23_P203137 UBE4A NM_004788 1.34 ubiquitin conjugation factor E4 A: Binds to the ubiquitin moieties of preformed conjugates and
catalyzes ubiquitin chain assembly in conjunction with E1, E2, and E3.
A_23_P152066 UBR1 NM_174916 1.33 ubiquitin protein ligase E3 component n-recognin 1: E3 ubiquitin-protein ligase which is a component
of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that
are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent
degradation. Plays a critical role in chromatin inactivation and chromosome-wide transcriptional
silencing during meiosis via ubiquitination of histone H2A. Binds leucine and is a negative regulator
of the leucine-mTOR signaling pathway, thereby controlling cell growth.
A_23_P362637 UBR2 NM_015255 1.25 ubiquitin protein ligase E3 component n-recognin 2: Same as for UBR1
A_32_P178945 YOD1 NM_018566 1.52 YOD1 OTU deubiquinating enzyme 1 homolog alias HIV-1-induced protease: Hydrolase that can remove
conjugated ubiquitin from proteins and participates in endoplasmic reticulum-associated degradation
(ERAD) for misfolded lumenal proteins. May act by triming the ubiquitin chain on the associated
substrate to facilitate their threading through the VCP/p97 pore. Ubiquitin moieties on substrates may
present a steric impediment to the threading process when the substrate is transferred to the VCP
pore and threaded through VCP’s axial channel. Mediates deubiquitination of both ‘Lys-48’- and ‘Lys-
63’-linked polyubiquitin chains. Able to cleave both polyubiquitin and di-ubiquitin.
A total of nine genes among 206 related to the ubiquitin/proteasome system (UPS) were significantly upregulated in lymphocytes from ALS patients compared
to controls, as determined by SAM (q < 1%) and LIMMA analyses (p < 0.001). Among them, four genes encode E3 ubiquitin ligases (RNF149, TRIM22, UBR1,a n d
UBR2) and one gene a deubiquitinase (YOD1).
aAgilent Array 4 × 44K probe IDs,
bgene symbol,
gNCBI GenBank accession number,
δfold change in expression and
εGeneCard functional description (http://www.genecards.org) are provided.
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Page 12 of 19Assessment of alteration of UPS-related gene expression
in lymphocytes from ALS patients based on microarray
data
Correlation of ANAPC4, SHFM, SUGT1, UBR1 and
UBR2 with demographic and disease parameters was
determined. Among these five genes, UBR2 (Ubiquitin-
protein ligase E3-alpha-2) encoded protein is known to
act in conjunction with UBR1 in a quality control path-
way for degradation of unfolded cytosolic proteins [39].
We calculated Spearman correlation between expression
data and length of the disease from symptom onset and
the ALS Functional Rating Scale-Revised score
(ALSFRS-R) at the time of peripheral blood sampling.
Significant correlation was found between UBR2
increased gene expression and time of disease from
onset to time of lymphocyte sampling (r = -0.8091, p =
0.0039), as well as ALSFRS-R (r = 0.6333, p = 0.0402)
(Figure 3, Table 8). Similar to Saris et al. (2009) [11], we
found no correlation between the expression of these
genes with gender, age at onset, age at collection, and
site of onset. However, unlike Saris et al. (2009) [11] but
similar to Zhang et al. (2006) [13] we present correla-
tions of individual genes with disease duration and
ALSFRS-R.
Assessment of alteration of the UPS in PBMCs from ALS
patients using proteasome inhibition assays
We employed the MG132 proteasome inhibition assay
to test whether the UPS transcriptional alterations
described above are accompanied by ubiquitination
changes at the protein level. MG132 blocks the proteo-
lytic activity of the 26S proteasome complex reversibly,
which inhibits the degradation of ubiquitin-conjugated
proteins and has multiple effects including, for instance,
reducing muscle atrophy associated with disuse [40] or
increasing caspase-mediated generation of TDP-43 C-
terminal fragments [41]. We prepared peripheral blood
mononuclear cell (PBMC) short-term cultures from ALS
patients (n = 6) and healthy control subjects (n = 5).
High molecular weight (HMW) poly-ubiquitinated pro-
tein forms were detected in protein lysates of these
PBMCs by Western blot analysis using monoclonal anti-
ubiquitin antibody similarly to Jury et al. (2003) [42].
For PBMCs from healthy control subjects, cultured in
RPMI [10% FCS] medium, accumulation of HMW poly-
ubiquitinated proteins was induced by MG132 treat-
ment, but this accumulation was partially mitigated by
the supplementation of the RPMI [10% FCS] medium
with matched autologous human serum at a final con-
centration of 20% (Figure 4). For PBMCs from ALS
patients, cultured in RPMI [10% FCS] medium, accumu-
lation of HMW poly-ubiquinated proteins was induced
by MG132 treatment, and this accumulation was further
increased by addition of autologous human serum from
each ALS patient (Figure 4).
Discussion
We report, for the first time, genome-wide expression
profiling of purified lymphocytes from patients with
amyotrophic lateral sclerosis. This study, performed
with the long oligonucleotide Agilent Human Whole
Genome 44 × 4K Array, demonstrates that ALS relevant
differential gene expression and pathway perturbations
can be identified in peripheral blood lymphocytes by a
functional enrichment method such as SAFE [20] and
not only in brain or spinal cord that are directly affected
by the disease. In the search for blood biomarkers in
neurological disorders, determination of molecular sig-
n a t u r e so rp a t h w a ya l t e r a t i o n sb e c o m e sc r i t i c a li nt h e
analysis of microarray data generated from the blood
compartment. This is due to the fact that at the gen-
ome-wide scale of gene expression, relevant biological
differences may be modest or even negligible relative to
the noise. The expression profiling studies on whole
b l o o df r o mA L Sp a t i e n t sb yS a r i set al. (2009) [11] and
Lin et al. (2009) [10] clearly illustrate the challenge for
data interpretation when variations in gene expression
are minimal and performed by different methods. In the
first case, 2300 probe-encoded genes were differentially
expressed with fold changes in expression (ALS vs.c o n -
trols) varying from 1.015 to 1.588 (mean value ± SD =
1.097 ± 0.073). In the second case, Lin et al. (2009) also
reported small fold changes in expression of four mito-
chondrial genes of the electron transport chain (FLAD1,
RFK, CYCS,a n dSDHB). A broader range of fold
c h a n g e si ne x p r e s s i o nf o rs u b c u l t u r e dP B M C sw a s
reported in the work by Zhang et al. (2011) [13] which
could be due to subculture conditions and/or the
method chosen for normalization of the microarray data
[43,44]. In our study, fold changes in expression for the
genes found significant by SAM and LIMMA (i.e.
DS3500), varied from 1.244 to 3.422 (mean value ± SD
= 1.556 ± 0.28). Therefore, one may not expect to corre-
late differential expression by qRT-PCR for many genes
due to the large sample size required to eventually con-
firm small changes in expression. This problem is par-
tially circumvented by global pathway analysis methods.
Many differentially expressed genes identified by SAM
and LIMMA may be subjectively placed in the context
of ALS pathogenesis. In addition, there was little overlap
with 166 genes that were found associated with ALS to
a variable degree in several single-gene and genome-
wide association studies (GWAS). For instance,
TARDBP, SOD1, KIFAP3 and COX7C were differentially
expressed in our study. TARDBP and SOD1, clearly
associated with ALS pathogenesis, have also been
Mougeot et al. BMC Medical Genomics 2011, 4:74
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Page 13 of 19Figure 3 Relationship between UBR2 transcriptional expression in lymphocytes from ALS patients and progression of the disease.
Expression of UBR2 varies inversely with the length of the disease from onset to lymphocyte gene expression testing, and varies directly with
the ALS-FRS-R score. Duration of the disease from onset to sampling (i.e. Disease Duration) (a) (*three close values) or the ALSFRS-R score at the
time of sampling (b) are indicated on the x-axis. Log2 ratios of expression obtained from the dual mode reference design are represented on
the y axis. Dot plot (c) shows that with a cut-off of 0.15, discrimination between ALS patients [ALS] and healthy controls [HC] for UBR2
expression is achieved with p = 0.000953 (Fisher’s exact test).
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Page 14 of 19identified by various genetic analyses for their associa-
tion with ALS. The fact that SAFE, LIMMA, and SAM
identified SOD1 mRNA upregulation to be significant
confirms findings by Gagliardi et al. (2010). Gagliardi et
al. showed that SOD1 mRNA levels were increased in
spinal cord, brain stem, and lymphocytes of sporadic
ALS patients, but did not correlate with gender, age or
duration of the disease [12].
For the first time, gene expression data from the blood
compartment from sporadic ALS patients could be asso-
ciated with the KEGG ALS disease pathway and KEGG
disease pathways of neurodegenerative disorders such as
Alzheimer’s, Parkinson’s and Huntington’s diseases.
Considering that global genome-wide subtle changes in
gene expression were used for this determination, this
result is rather unexpected. Protein activity changes that
are caused by the presence of the disease are generally
not expected to consistently correspond to transcrip-
tional regulations. Our use of purified lymphocytes has
likely provided a better dataset to study ALS-specific
signature in the blood compartment as opposed to total
blood.
H o w e v e r ,b e c a u s eo ft h es m a l ls a m p l es i z eo fo u r
study (n = 22) and because ALS is a heterogeneous dis-
ease, it is not possible to capture the breadth of the dis-
ease process occurring during onset and progression of
the disease. In addition, disease responses in lympho-
cytes may not mirror many of the disease processes
occurring in brain, which depend on the alteration of
the blood brain barrier and the microenvironment
represented by glia and microglia. Furthermore, assum-
ing that transcriptional regulation produces more or less
active protein with appropriate subcellular localization
and in a timely manner, about half of the genes based
on their expression would have a negative effect on
motor neuron survival while the rest would have a
positive effect according to current ALS literature
(Table 6). This clearly indicates very limited replication
of processes occurring in brain or spinal cord of ALS
patients. Thus, while similar pathways are affected in
motor neurons and lymphocytes due to a possible sys-
temic common cause(s), it is expected that some
responses may differ in their details possibly reflecting
differential susceptibility.
In our pathway analysis of the dataset DS7000 gener-
ated with Agilent Human Whole Genome 4 × 44K
Array, SAFE identified alteration of gene expression per-
taining to gene ontology (GO) categories relevant to
ALS pathogenesis (and/or other neurological diseases),
such as DNA metabolism, RNA splicing, mitochondrial
f u n c t i o n ,o x i d a t i o n ,E Ra n dG o l g if u n c t i o n s ,U P S ,n e u -
rological function, post-translational modification and
viral infection. These results are consistent with findings
by Saris et al. (2009) that were determined by whole
blood RNA profiling [11]. However, following pathway
analysis using SAFE, we went further in the analysis of
transcriptional alterationso ft h eU P Sb yi d e n t i f y i n ga
correlation between the expression of differentially
expressed individual UPS-related genes and the time of
presence of the disease or the ALSFRS-R. Indeed, whole
exome sequencing identified mutations in the gene
encoding valosin-containing protein (VCP), a key com-
ponent of the UPS, as a cause of familial ALS, demon-
strating that disturbances of UPS function may be
closely linked to ALS pathogenesis [45]. A total of nine
differentially expressed genes, were related to the UPS
including four ubiquitin ligases representative of UPS
GO groups identified by SAFE (ANAPC4, SHFM1,
UBR1,a n dUBR2). Differential expression of the “N-end
rule” ubiquitin ligase UBR2 gene [46] in lymphocytes
from ALS patients was found to correlate with disease
d u r a t i o na n dA L S F R S - Ra tt h et i m eo fs a m p l i n g .
Although, overall UBR2 mRNA expression is upregu-
lated in ALS patients compared to healthy controls, a
decrease in expression correlated with more advanced
stage or severity. This apparent paradox can be
explained by the possibility that an initial disease pro-
cess to which healthy controls are never exposed, causes
an initial upregulation of UBR2 mRNA expression
which then declines as the disease progresses with
increasing impairment of the UPS machinery. One pos-
sible mechanism of action of E3 ubiquitin ligases UBR1
and UBR2 could be to facilitate targeting of foldable
conformers to the proteasome [39] and to provide pro-
tection against toxicity of (unknown) misfolded proteins
that accumulate during the disease course in lympho-
cytes from ALS patients. This mechanism is similar to
the E3 ubiquitin ligase dorfin (encoded by RNF19A) that
prevents mutant SOD1-mediated neurotoxicity and
improves symptoms in the transgenic G93A SOD1
Table 8 Correlation between expression data of
differentially expressed UPS genes and ALSFRS-R or
disease duration
Spearman Correlation
Gene Probe Disease Duration ALSFRS-R
ANAPC4 A_23_P317800 r = -0.0364 r = -0.2642
p = 0.9241 p = 0.4348
SHFM1 A_23_P42664 r = 0.3909 r = -0.3144
p = 0.2366 p = 0.3415
SUGT1 A_23_P162787 r = 0.3636 r = -0.3736
p = 0.2731 p = 0.2608
UBR1 A_23_P152066 r = 0.0636 r = 0.2323
p = 0.8603 p = 0.4854
UBR2 A_23_P362637 r = -0.8091 r = 0.6333
p = 0.0039* p = 0.0402*
*p < 0.05
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Page 15 of 19Figure 4 Total ubiquitination Western blot (WB) analysis of cultured PBMCs from ALS patients and controls in the presence or
absence of added-back serum for 16 hours and treated or not with proteasome inhibitor MG132 for 1.5 hr. Comparison of PBMCs from
one healthy control and one ALS patient incubated or not in the presence of added-back matched autologous serum is shown in (a). Semi-
quantitative Western blot analysis was performed to measure the accumulation of high molecular weight (HMW) ubiquitinated protein species in
PBMCs that were prepared the same day from one healthy control and one ALS patient (WB1). A signal (S) to noise (N) ratio (S/N) was
determined with ImageJ program by comparing the integrated density of two areas consistently stained throughout the membrane and visually
contrasting the accumulation of HMW ubiquitinated protein species (WB1). ALS patient serum exacerbates the effects of MG132 on total
ubiquitination and accumulation of HMW ubiquitinated species, while serum from healthy control mitigates these effects. Comparison of PBMCs
from ALS patients (n = 5) and healthy controls (n = 4) incubated in the presence of added-back matched autologous serum is shown in (b).
PBMCs obtained at different times from additional ALS patients (n = 5) and healthy controls (n = 4) show similar result (WB2 and WB3).
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Page 16 of 19mouse model [47,48]. Indeed, the presence of some cel-
lular toxicity in PBMCs was shown by De Marco et al.
(2010) [49] who determined that the cytoplasmic frac-
tion of TDP-43 in circulating PBMCs of sporadic and
familial ALS patients was increased. In addition, by ana-
logy with mutant SOD1-mediated toxicity, human wild-
type TDP-43-mediated neurotoxicity might be partially
alleviated by co-expression with ubiquilin 1 (encoded by
UBQLN1) involved in autophagy and proteasome target-
ing [50,51]. Moreover, mutations in ubiquilin 2
(encoded by UBQLN2) have been associated with X-
linked juvenile ALS and adult sporadic ALS [52]. Ubi-
quilins bind to both ubiquitin ligases and the protea-
some, providing a connector function within the UPS
[53].
Our proteasome inhibition assays also indicate that
lymphocytes from ALS patients exposed to serum fac-
tors and metabolites in vivo have acquired new proper-
ties with regard to the UPS and other pathways that are
normally perturbed in degenerating motor neurons. In
this respect, the study by Watanabe et al. (2010) [54],
showing that metabolic alterations of the UPS may take
place in the skin of ALS patients, follows the same para-
digm. In addition, using short-term PBMC cultures
Zhang et al. (2011) [13] showed that monocytes in ALS
patients have acquired unique properties that relate to
neuroinflammation and innate immunity.
Conclusions
Our approach demonstrates that subtle changes in gene
expression measured by Agilent Human Whole Genome
4 × 44K Array may be interpreted objectively. Without
underestimating the complexity of ALS pathogenesis,
our analyses with these arrays identify multiple new
directions worth further investigation, including sys-
temic UPS pathway alterations, in the search of biomar-
kers associated with the cause(s) or the progression of
ALS. Overall, it remains to be determined which proper-
ties the circulating lymphocytes acquire by long distance
signaling in the peripheral blood system, and which
properties they acquire by local signaling or local cell-
cell contact due to trafficking of the lymphocytes at the
sites of neurodegeneration in brain or spinal cord.
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